The biopharmaceutical industry stands at a crossroads. The era of blockbuster drugs, once the lifeblood of big pharma, is waning. […]
As blockbuster drugs fizzle, biotech looks warily to the next big thing Read Post »
File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food
By Dylan Scott, Posted with permission from STAT Mark Cuban has something to say about prescription drug prices. The billionaire
Some Biosimilars Are Just as Good as Some Pricey Biologics: A Game-Changer in Healthcare In the world of medicine, we’re
Some biosimilars are just as good as some pricey biologics Read Post »
Thank you for your interest in submitting a guest article! Submit your guest article here DrugPatentWatch is interested in sharing
Hermann A. M. Mucke*, H. M. Pharma Consultancy, Wien, Austria A Multimodal Approach to the Re-development of Drugs Drug repositioning—the
Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory Read Post »
Share your expertise with our expansive network > Go to submission form < Do you want to reach a large
Subscribe to our weekly newsletter below and never miss the latest product or an exclusive offer.
